Globus Medical reports positive 7-year results for SECURE-C vs. ACDF trial

Written by Megan Wood | December 01, 2017 | Print  |

Globus Medical reported clinical results from its seven-year trial follow-up on the SECURE-C Cervical Artificial Disc.

SECURE-C is intended for disc reconstruction and motion preservation at the disc under operation. The Investigational Device Exemption trial, inclusive of 380 patients, compared the SECURE-C to anterior cervical discectomy and fusion using a cervical plate and structural allograft. The patients suffered from intractable symptomatic cervical disc disease at a single level.


Here are seven-year, postsurgery data points:


1. Patients with the SECURE-C reported greater overall satisfaction compared to ACDF patients.

2. Of the SECURE-C group, 86.3 percent saw statistically superior composite overall success results compared to ACDF patients at 70 percent.


3. Eighty-six percent of the ACDF patients saw Neck Disability Index pain and function improvement compared to 90.4 percent of the SECURE-C group.


4. The SECURE-C patients experienced a lower rate of subsequent surgery at the operated level compared to ACDF patients.


5. ACDF patients had a higher rate of adjacent level surgery compared to SECURE-C patients.


More articles on devices:
SpineGuard receives 1st PediGuard order from Chinese medical group — 4 points
300th surgical spine case using K2M’s Rhine Cervical Disc System complete: 5 things to know
Stryker subsidiary settles trade secret case with Zimmer Biomet: 5 insights

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months